Wild‐type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma
暂无分享,去创建一个
[1] T. Enomoto,et al. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin , 2009, International journal of cancer.
[2] J. Kigawa,et al. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma , 2008, Cancer science.
[3] H. Kawasaki,et al. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma , 2006, Proteomics.
[4] Kathleen R. Cho,et al. Classifications of ovarian cancer tissues by proteomic patterns , 2006, Proteomics.
[5] Takako Yamada,et al. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. , 2006, Cancer letters.
[6] S. Altmann,et al. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. , 2005, Analytical biochemistry.
[7] David P Lane,et al. p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.
[8] Kuang-Yu Jen,et al. Identification of novel p53 target genes in ionizing radiation response. , 2005, Cancer research.
[9] F. Bray,et al. Ovarian cancer in Europe: Cross‐sectional trends in incidence and mortality in 28 countries, 1953–2000 , 2005, International journal of cancer.
[10] C. Scharf,et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. , 2004, Cancer letters.
[11] Patrick Dowd,et al. The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.
[12] S. Moss,et al. The annexins , 2004, Genome Biology.
[13] Muyang Li,et al. Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.
[14] Trevor Hastie,et al. Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.
[15] B. Kishore,et al. Annexin A4 Reduces Water and Proton Permeability of Model Membranes but Does Not Alter Aquaporin 2–mediated Water Transport in Isolated Endosomes , 2003, The Journal of general physiology.
[16] Guillermina Lozano,et al. Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.
[17] T. Lawrence,et al. Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells , 2003, Cancer biology & therapy.
[18] T. Okai,et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. , 2003, Gynecologic oncology.
[19] Kathleen R. Cho,et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.
[20] Mitsuaki Suzuki,et al. Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary , 2002, Obstetrics and gynecology.
[21] Mitsuaki Suzuki,et al. Mechanisms of Cisplatin Resistance in Clear Cell Carcinoma of the Ovary , 2002, Oncology.
[22] Chao‐Ping Yang,et al. Infrequent p53 Gene Mutations and Lack of p53 Protein Expression in Clear Cell Sarcoma of the Kidney: Immunohistochemical Study and Mutation Analysis of p53 in Renal Tumors of Unfavorable Prognosis , 2002, Modern Pathology.
[23] M. Saegusa,et al. Possible associations among expression of p14ARF, p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas , 2001, Cancer.
[24] K. Vousden,et al. Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.
[25] H. Ohkawa,et al. Differential lipid specificities of the repeated domains of annexin IV. , 2001, Biochimica et biophysica acta.
[26] Y. Hsieh,et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. , 2001, Gynecologic oncology.
[27] M. Pierotti,et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] N. Collins,et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines , 2000, British Journal of Cancer.
[29] T. Nikaido,et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas , 1999, Cancer.
[30] D. Lane,et al. The p53 tumour suppressor gene , 1998, The British journal of surgery.
[31] M. Morgan,et al. Clinical characteristics of clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.
[32] D. Meek,et al. Multisite phosphorylation and the integration of stress signals at p53. , 1998, Cellular signalling.
[33] G. Casey,et al. p53 overexpression is Not an independent prognostic factor for patients with primary ovarian epithelial cancer , 1997, Cancer.
[34] A. Børresen-Dale,et al. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas , 1997, The Journal of pathology.
[35] M. Kaetzel,et al. Inositol 3,4,5,6-Tetrakisphosphate Inhibits the Calmodulin-dependent Protein Kinase II-activated Chloride Conductance in T84 Colonic Epithelial Cells* , 1996, The Journal of Biological Chemistry.
[36] E. Miyagi,et al. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. , 1995, Gynecologic oncology.
[37] P. Sismondi,et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma , 1995, Cancer.
[38] R. Bast,et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. , 1993, Journal of the National Cancer Institute.
[39] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[40] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[41] Medicine,et al. Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.
[42] H. Kawasaki,et al. Mutagenesis of longer inserts by the ligation of two PCR fragments amplified with a mutation primer. , 2009, Journal of bioscience and bioengineering.
[43] R. Figlin,et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. , 2007, The Journal of urology.
[44] E. Miyagi,et al. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. , 1997, British Journal of Cancer.